These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 20592377)
1. IL-6 and VEGF in small cell lung cancer patients. Wójcik E; Jakubowicz J; Skotnicki P; Sas-Korczyńska B; Kulpa JK Anticancer Res; 2010 May; 30(5):1773-8. PubMed ID: 20592377 [TBL] [Abstract][Full Text] [Related]
2. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424 [TBL] [Abstract][Full Text] [Related]
3. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951 [TBL] [Abstract][Full Text] [Related]
4. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Schneider J; Philipp M; Salewski L; Velcovsky HG Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474 [TBL] [Abstract][Full Text] [Related]
5. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
6. [The evaluation to relationship between serum vascular endothelial growth factor (VEGF) level, metastases and other tumor markers in patients with lung cancer]. Sağlam DA; Ursavaş A; Karadağ M; Yilmaztepe Oral A; Coşkun F; Gözü RO Tuberk Toraks; 2008; 56(1):50-5. PubMed ID: 18330755 [TBL] [Abstract][Full Text] [Related]
7. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109 [TBL] [Abstract][Full Text] [Related]
8. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
9. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer. Ono A; Naito T; Ito I; Watanabe R; Shukuya T; Kenmotsu H; Tsuya A; Nakamura Y; Murakami H; Kaira K; Takahashi T; Kameya T; Nakajima T; Endo M; Yamamoto N Lung Cancer; 2012 Jun; 76(3):439-44. PubMed ID: 22300752 [TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098 [TBL] [Abstract][Full Text] [Related]
12. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381 [TBL] [Abstract][Full Text] [Related]
13. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients. Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710 [TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392 [TBL] [Abstract][Full Text] [Related]
15. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. Bubanović G; Pavićević R; Franjević A Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223 [TBL] [Abstract][Full Text] [Related]
16. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461 [TBL] [Abstract][Full Text] [Related]
17. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547 [TBL] [Abstract][Full Text] [Related]
18. ProGRP: a new biomarker for small cell lung cancer. Molina R; Filella X; Augé JM Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231 [TBL] [Abstract][Full Text] [Related]
19. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer. Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590 [TBL] [Abstract][Full Text] [Related]
20. [The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer]. Chen YJ; Jin WD; Yang GY; Zhou YL Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):381-3. PubMed ID: 22338231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]